365 related articles for article (PubMed ID: 31148598)
1. A bioprinted human-glioblastoma-on-a-chip for the identification of patient-specific responses to chemoradiotherapy.
Yi HG; Jeong YH; Kim Y; Choi YJ; Moon HE; Park SH; Kang KS; Bae M; Jang J; Youn H; Paek SH; Cho DW
Nat Biomed Eng; 2019 Jul; 3(7):509-519. PubMed ID: 31148598
[TBL] [Abstract][Full Text] [Related]
2. Patient-specific 3D-printed glioblastomas.
Gomez-Roman N; Chalmers AJ
Nat Biomed Eng; 2019 Jul; 3(7):498-499. PubMed ID: 31148599
[No Abstract] [Full Text] [Related]
3. Engineered 3D tumour model for study of glioblastoma aggressiveness and drug evaluation on a detachably assembled microfluidic device.
Ma J; Li N; Wang Y; Wang L; Wei W; Shen L; Sun Y; Jiao Y; Chen W; Liu J
Biomed Microdevices; 2018 Sep; 20(3):80. PubMed ID: 30191323
[TBL] [Abstract][Full Text] [Related]
4. Molecular crosstalk between tumour and brain parenchyma instructs histopathological features in glioblastoma.
Bougnaud S; Golebiewska A; Oudin A; Keunen O; Harter PN; Mäder L; Azuaje F; Fritah S; Stieber D; Kaoma T; Vallar L; Brons NH; Daubon T; Miletic H; Sundstrøm T; Herold-Mende C; Mittelbronn M; Bjerkvig R; Niclou SP
Oncotarget; 2016 May; 7(22):31955-71. PubMed ID: 27049916
[TBL] [Abstract][Full Text] [Related]
5. Inhibition of Cyclin D1 Expression in Human Glioblastoma Cells is Associated with Increased Temozolomide Chemosensitivity.
Zhang D; Dai D; Zhou M; Li Z; Wang C; Lu Y; Li Y; Wang J
Cell Physiol Biochem; 2018; 51(6):2496-2508. PubMed ID: 30562739
[TBL] [Abstract][Full Text] [Related]
6. A Model to Predict the Feasibility of Concurrent Chemoradiotherapy With Temozolomide in Glioblastoma Multiforme Patients Over Age 65.
Putz F; Knippen S; Lahmer G; Fietkau R; Semrau S
Am J Clin Oncol; 2017 Oct; 40(5):523-529. PubMed ID: 26017481
[TBL] [Abstract][Full Text] [Related]
7. Rindopepimut with temozolomide for patients with newly diagnosed, EGFRvIII-expressing glioblastoma (ACT IV): a randomised, double-blind, international phase 3 trial.
Weller M; Butowski N; Tran DD; Recht LD; Lim M; Hirte H; Ashby L; Mechtler L; Goldlust SA; Iwamoto F; Drappatz J; O'Rourke DM; Wong M; Hamilton MG; Finocchiaro G; Perry J; Wick W; Green J; He Y; Turner CD; Yellin MJ; Keler T; Davis TA; Stupp R; Sampson JH;
Lancet Oncol; 2017 Oct; 18(10):1373-1385. PubMed ID: 28844499
[TBL] [Abstract][Full Text] [Related]
8. Exosomal transfer of miR-151a enhances chemosensitivity to temozolomide in drug-resistant glioblastoma.
Zeng A; Wei Z; Yan W; Yin J; Huang X; Zhou X; Li R; Shen F; Wu W; Wang X; You Y
Cancer Lett; 2018 Nov; 436():10-21. PubMed ID: 30102952
[TBL] [Abstract][Full Text] [Related]
9. Targeted nanocomplex carrying siRNA against MALAT1 sensitizes glioblastoma to temozolomide.
Kim SS; Harford JB; Moghe M; Rait A; Pirollo KF; Chang EH
Nucleic Acids Res; 2018 Feb; 46(3):1424-1440. PubMed ID: 29202181
[TBL] [Abstract][Full Text] [Related]
10. 18F-FET microPET and microMRI for anti-VEGF and anti-PlGF response assessment in an orthotopic murine model of human glioblastoma.
Nedergaard MK; Michaelsen SR; Urup T; Broholm H; El Ali H; Poulsen HS; Stockhausen MT; Kjaer A; Lassen U
PLoS One; 2015; 10(2):e0115315. PubMed ID: 25680186
[TBL] [Abstract][Full Text] [Related]
11. ATP binding cassette (ABC) transporters: expression and clinical value in glioblastoma.
Dréan A; Rosenberg S; Lejeune FX; Goli L; Nadaradjane AA; Guehennec J; Schmitt C; Verreault M; Bielle F; Mokhtari K; Sanson M; Carpentier A; Delattre JY; Idbaih A
J Neurooncol; 2018 Jul; 138(3):479-486. PubMed ID: 29520610
[TBL] [Abstract][Full Text] [Related]
12. Benefit and outcome of using temozolomide-based chemoradiotherapy followed by temozolomide alone for glioblastoma in clinical practice.
Salma S; Djan I; Bjelan M; Vulekovic P; Novakovic M; Vidovic V; Lucic M
J BUON; 2017; 22(5):1233-1239. PubMed ID: 29135107
[TBL] [Abstract][Full Text] [Related]
13. Afatinib and Temozolomide combination inhibits tumorigenesis by targeting EGFRvIII-cMet signaling in glioblastoma cells.
Vengoji R; Macha MA; Nimmakayala RK; Rachagani S; Siddiqui JA; Mallya K; Gorantla S; Jain M; Ponnusamy MP; Batra SK; Shonka N
J Exp Clin Cancer Res; 2019 Jun; 38(1):266. PubMed ID: 31215502
[TBL] [Abstract][Full Text] [Related]
14. Rapid 3D Bioprinting of Glioblastoma Model Mimicking Native Biophysical Heterogeneity.
Tang M; Tiwari SK; Agrawal K; Tan M; Dang J; Tam T; Tian J; Wan X; Schimelman J; You S; Xia Q; Rana TM; Chen S
Small; 2021 Apr; 17(15):e2006050. PubMed ID: 33502104
[TBL] [Abstract][Full Text] [Related]
15. Nuclear factor I A promotes temozolomide resistance in glioblastoma via activation of nuclear factor κB pathway.
Yu X; Wang M; Zuo J; Wahafu A; Mao P; Li R; Wu W; Xie W; Wang J
Life Sci; 2019 Nov; 236():116917. PubMed ID: 31614149
[TBL] [Abstract][Full Text] [Related]
16. PLK4 is a determinant of temozolomide sensitivity through phosphorylation of IKBKE in glioblastoma.
Zhang Z; Wang Z; Huang K; Liu Y; Wei C; Zhou J; Zhang W; Wang Q; Liang H; Zhang A; Wang G; Zhen Y; Han L
Cancer Lett; 2019 Feb; 443():91-107. PubMed ID: 30529153
[TBL] [Abstract][Full Text] [Related]
17. Long non-coding RNA TUSC7 inhibits temozolomide resistance by targeting miR-10a in glioblastoma.
Shang C; Tang W; Pan C; Hu X; Hong Y
Cancer Chemother Pharmacol; 2018 Apr; 81(4):671-678. PubMed ID: 29397407
[TBL] [Abstract][Full Text] [Related]
18. MPC1 deletion is associated with poor prognosis and temozolomide resistance in glioblastoma.
Chai Y; Wang C; Liu W; Fan Y; Zhang Y
J Neurooncol; 2019 Sep; 144(2):293-301. PubMed ID: 31236818
[TBL] [Abstract][Full Text] [Related]
19. The Evaluation of Glioblastoma Cell Dissociation and Its Influence on Its Behavior.
Skarkova V; Krupova M; Vitovcova B; Skarka A; Kasparova P; Krupa P; Kralova V; Rudolf E
Int J Mol Sci; 2019 Sep; 20(18):. PubMed ID: 31540507
[TBL] [Abstract][Full Text] [Related]
20. Quantitative Clinical Imaging Methods for Monitoring Intratumoral Evolution.
Kim JY; Gatenby RA
Methods Mol Biol; 2017; 1513():61-81. PubMed ID: 27807831
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
